WOONSOCKET – CVS Caremark, CVS Health Corp.’s pharmacy benefit manager, has reached a settlement with the Federal Trade Commission over insulin prices and rebate practices. The agreement resolves the FTC’s 2024 lawsuit alleging CVS Caremark, Express Scripts Inc. and Optum Inc. used unfair rebating practices to inflate insulin list prices, limiting access to lower-cost drugs and shifting costs to
Already a Subscriber? Log in
To Continue Reading This Article
Become a Providence Business News subscriber and get immediate access to all of our premier content and much more.Learn More and Become a Subscriber
- Critical RI business news and analysis updated daily.
- 1 year of print (26 issues).
- Unlimited access to all subscriber only content on our website, on any device.
- Free email alerts.
- Annual Book of Lists Print Edition.
- All special issues produced during subscription term.
Click Here to purchase a paywall bypass link for this article
PBN Branded Content
Seifert Systems Invests in Energy Efficiency to Strengthen Operations
For manufacturers, energy is more than just another operating expense. It plays a critical role…
Learn More
